Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1991 Mar;34(2):71–73. doi: 10.1007/BF01741338

An overview of radioimmunotherapy

A Maraveyas 1,✉, A A Epenetos 1
PMCID: PMC11038270  PMID: 1760818

Abstract

In reviewing the current state of affairs in radioimmunotherapy the paper focuses on the main difficulties thus far encountered and the procedures designed to avoid or circumvent these problems. The long range β-emitters90Y and188Re have replaced131I as the isotopes currently receiving most attention for use in radioimmunotherapy, and a range of new chelators are under investigation for in vivo stability and immunogenicity. Approaches aimed at improving tumour targetting and antigen expression such as two-step pretargetting techniques, tumour necrosis treatment and cytokine pretreatment are summarised. Methods designed to improve host-Mab interactions are outlined and the need to incorporate successful ideas from current cancer therapies is emphasised.

Key words: Radioimmunotherapy

References

  • 1.Abrams PG, Carrasquillo JA, Schroff RW, Eary JF, Fritzberg AR, Morgan AC, Wilbur DS, Beaumier PL, Larson SM, Nelp WB (1987) Imaging and therapy of metastatic carcinoma with radiolabeled monoclonal antibodies. Princ Cancer Biother 337–354
  • 2.Bejent RHJ. Dosimetry and suppression of the anti-mouse response in131I labelled antibody therapy of cancer. Br J Cancer. 1989;59:305. [Google Scholar]
  • 3.Benjamin RJ, Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature. 1986;320:449. doi: 10.1038/320449a0. [DOI] [PubMed] [Google Scholar]
  • 4.Boyd JE, James K. Human monoclonal antibodies: their potential, problems and prospects. Adv Biotechnol Processes. 1989;11:1–43. [PubMed] [Google Scholar]
  • 5.Bosslet K, Steinstraesser A, Hermentin P, Kuhlman L, Broynck A, Magerstaedt M, Seemann G, Schwarz A, Sedlacek HH. Generation of bispecific monoclonal antibodies for two-phase radioimmunotherapy. In: Epenetos AA, editor. Monoclonal antibodies, applications in clinical oncology. Lond: Chapman & Hall; 1991. pp. 167–178. [Google Scholar]
  • 6.Britton KE. Overview of radioimmunotherapy: a European perspective. Antibody Immunoconjugates Radiopharmaceuticals. 1991;4:133–150. [Google Scholar]
  • 7.Deshpande SV, DeNardo SJ, Kukis DL, Moi MK, McCall MS, DeNardo GL, Meares CF. Yttrium-90 labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med. 1990;31:473–479. [PubMed] [Google Scholar]
  • 8.Epstein AL, Chen FM, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res. 1988;48:5842–5848. [PubMed] [Google Scholar]
  • 9.Epstein AL, Chen FM, Ansari A, Najafi A, Siegel M, Lee K, Hu E, Rosen P, Watkins P, Stain S, Wearer F, Taylor C. Radioimmunodetection of necrotic lesions in human tumours using I-131 labelled TNT-1 F(ab′)2 monoclonal antibody. Antibody Immunoconjugates Radiopharmaceuticals. 1991;4:151–161. [Google Scholar]
  • 10.Goldenberg DM, Blumenthal RD, Sharkey RM. Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies. Semin Cancer Biol. 1990;1:217–225. [PubMed] [Google Scholar]
  • 11.Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294. [PubMed] [Google Scholar]
  • 12.Hooker GR, Epenetos AA (1986) The intracavitary application of monoclonal antibodies as vehicles for therapeutic radionucleotides. In: Schubiger PA and Hassler PH (eds) Radionuclides for therapy. Roche Scientific Service Publications, pp 183–199
  • 13.Humm JL. Dosimetric aspects of radiolabeled antibodies for tumour therapy. J Nucl Med. 1986;27:1491–1497. [PubMed] [Google Scholar]
  • 14.Kohler S, Milstein G. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  • 15.Kosmas C, Snook D, Hird V, Gooden GS, Verhoeyen M, Courtenay-Luck NS, McCall MJ, Meares C, Epenetos AA (1991) Immune responses against the macrocyclic chelating agent (DOTA) in patients receiving anti-tumour monoclonal antibodies for imaging and therapy. Proc 8th Int Hammersmith Meet. Advances in the applications of monoclonal antibodies in clinical oncology. p 61
  • 16.Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targetting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358–1366. [PubMed] [Google Scholar]
  • 17.Moi MK, Meares CF, De Nardo SJ. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetracetic acid, and study of its yttrium (III) complex. J Am Chem Soc. 1988;110:6266. doi: 10.1021/ja00226a063. [DOI] [PubMed] [Google Scholar]
  • 18.Paganelli G, Malcovati M, Fazio F. Monoclonal antibody pretargetting techniques for tumour localisation: the avidin-biotin system. Nucl Med Commun. 1991;12:211–234. doi: 10.1097/00006231-199103000-00006. [DOI] [PubMed] [Google Scholar]
  • 19.Philpott GW, Shearer WT, Bower JR, Parker CW. Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. J Immunol. 1973;111:921. [PubMed] [Google Scholar]
  • 20.Pimm MV, Fells HF, Perkins AC, Baldwin RW. Iodine-131 and indium-111 labelled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonal antibody. Nucl Med Commun. 1988;5:931–941. doi: 10.1097/00006231-198811000-00010. [DOI] [PubMed] [Google Scholar]
  • 21.Riechmann L, Clark M, Waldman H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332:323–327. doi: 10.1038/332323a0. [DOI] [PubMed] [Google Scholar]
  • 22.Rosenblum MG, Lamki LM, Murray JL, Carlo DJ, Gutterman JV. Interferon-induced changes in pharmacokinetics and tumour uptake of111In-labelled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst. 1988;80:160–165. doi: 10.1093/jnci/80.3.160. [DOI] [PubMed] [Google Scholar]
  • 23.Rowlinson-Busza G, Bamias A, Krausz T, Epenetos AA. Uptake and distribution of specific and control monoclonal antibodies in subcutaneous xenographts following intratumour injection. Cancer Res. 1991;51:3251–3256. [PubMed] [Google Scholar]
  • 24.Sehon AH. Conversion of xenogeneic monoclonal antibodies to specific tolerogens. Br J Cancer. 1989;59:313. [Google Scholar]
  • 25.Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumour associated antibodies. Med Phys. 1984;11:638–645. doi: 10.1118/1.595559. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES